Ramipril + amlodipine fixed-dose combination resulted in higher 1-year treatment adherence compared to ramipril + hydrochlorothiazide (54% vs 29%; HR for discontinuation 2.318).
Cohort (n=39,095)
Does ramipril + amlodipine fixed-dose combination improve 1-year treatment adherence compared to ramipril + hydrochlorothiazide in patients with hypertension?
In patients with hypertension, a fixed-dose combination of ramipril and amlodipine is associated with significantly higher 1-year treatment adherence compared to a combination of ramipril and hydrochlorothiazide.
Effect estimate: HR 2.318 (95% CI 2.246-2.392)
Absolute Event Rate: 54% vs 29%
Objective To compare 1-year treatment adherence of ramipril + amlodipine and ramipril +hydroclorothiazide fixed-dose combination therapies in patients with hypertension. Methods Data were extracted from the database of the National Health Insurance Fund of Hungary. Treatment adherence was modelled using survival analysis. Results At 2 months after initiation of treatment, 42% of patients using ramipril +hydrochlorothiazide ( n = 28,800) had discontinued treatment, compared with 0% of patients using ramipril + amlodipine ( n = 10,295). At 1 year, treatment adherence was 29% in the ramipril + hydrochlorothiazide group and 54% in the ramipril + amlodipine group. The hazard ratio for discontinuing ramipril + hydrochlorothiazide vs ramipril + amlodipine was 2.318 (95% confidence intervals 2.246, 2.392). Conclusion Ramipril + amlodipine had significantly higher 1-year treatment adherence than ramipril + hydrochlorothiazide in patients with hypertension.
Simonyi et al. (Tue,) conducted a cohort in Hypertension (n=39,095). Ramipril + amlodipine vs. Ramipril + hydrochlorothiazide was evaluated on 1-year treatment adherence (HR 2.318, 95% CI 2.246-2.392). Ramipril + amlodipine fixed-dose combination resulted in higher 1-year treatment adherence compared to ramipril + hydrochlorothiazide (54% vs 29%; HR for discontinuation 2.318).